Mind Medicine Inc. (MNMD) is entering a period where the outcomes of multiple late-stage trials could determine the company's trajectory for years to come. With programs advancing in generalized anxiety disorder, major depressive disorder, and autism spectrum disorder, the next two years represent a critical test of whether its pipeline can deliver on its ambitious promise.
MM120 for Generalized Anxiety Disorder (GAD)
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com